FDA-cleared profile

CINA CHEST

Avicenna.AI · CT/CTA · FDA-cleared (510(k))

Authorized purpose: Radiological computer-aided triage and notification for chest CTA suspected pulmonary embolism and chest or thoraco-abdominal CTA suspected aortic dissection, assisting hospital networks and trained radiologists with workflow prioritization in parallel with standard-of-care interpretation.

Clinical role
Parallel triage and notification support; it does not alter the original image or provide a diagnostic result beyond notification, and clinicians remain responsible for full-image review.
Images and patients
CT/CTA · Chest and thoraco-abdominal aorta
Key limitation
Keep in mind: Notifications and compressed previews are informational and not for diagnosis; the device is not intended as a diagnostic device or to replace standard-of-care full-image interpretation. PE and AD are separate applications and performance endpoints.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Radiological computer-aided triage and notification for chest CTA suspected pulmonary embolism and chest or thoraco-abdominal CTA suspected aortic dissection, assisting hospital networks and trained radiologists with workflow prioritization in parallel with standard-of-care interpretation.
  • Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Chest and thoraco-abdominal aorta Input: Chest CTA for suspected PE and chest or thoraco-abdominal CTA for suspected AD, received as DICOM images through the CINA Platform or a compatible medical-image communications device.
  • Who uses it?Intended users: Hospital networks and trained radiologists; notified clinicians review full images under standard of care.
  • What does the software produce?Output: Worklist pop-up and passive icon notifications identifying suspected PE or AD, with patient name, accession number, finding type, and a compressed preview labeled not for diagnostic use; output files can be transferred to PACS or a workstation.
  • What is its most important limitation?Key limitation: Notifications and compressed previews are informational and not for diagnosis; the device is not intended as a diagnostic device or to replace standard-of-care full-image interpretation. PE and AD are separate applications and performance endpoints.

Clinical takeaway. Clinical role: Radiological computer-aided triage and notification for chest CTA suspected pulmonary embolism and chest or thoraco-abdominal CTA suspected aortic dissection, assisting hospital networks and trained radiologists with workflow prioritization in parallel with standard-of-care interpretation.

Evidence takeaway. Evidence from the reviewed source record: A retrospective multicenter blinded study included 396 PE cases from 230 U.S. cities/sites as stated in the packet and 298 AD cases from 200, with 190 positive PE and 137 positive AD cases; ground truth used concurrence of several U.S.-board-certified radiologists. PE sensitivity/specificity were 91.1% (95% CI 86.1%-94.7%) and 91.8% (87.1%-95.1%); AD sensitivity/specificity were 96.4% (91.7%-98.8%) and 97.5% (93.8%-99.3%). Overall agreement was 91.4% for PE and 97% for AD, MCC was 0.83 and 0.94, and mean time-to-notification was 63 seconds for PE and 36.5 seconds for AD. These are separate condition-specific sensitivity/specificity, agreement, correlation, and latency endpoints.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Radiological computer-aided triage and notification for chest CTA suspected pulmonary embolism and chest or thoraco-abdominal CTA suspected aortic dissection, assisting hospital networks and trained radiologists with workflow prioritization in parallel with standard-of-care interpretation.
  • Exact FDA submission
  • Checked 2026-09-09
Workflow role
Parallel triage and notification support; it does not alter the original image or provide a diagnostic result beyond notification, and clinicians remain responsible for full-image review.
  • Exact FDA submission
  • Checked 2026-09-09
Required input
Chest CTA for suspected PE and chest or thoraco-abdominal CTA for suspected AD, received as DICOM images through the CINA Platform or a compatible medical-image communications device.
  • Exact FDA submission
  • Checked 2026-09-09
Output and clinician action
Worklist pop-up and passive icon notifications identifying suspected PE or AD, with patient name, accession number, finding type, and a compressed preview labeled not for diagnostic use; output files can be transferred to PACS or a workstation.
  • Exact FDA submission
  • Checked 2026-09-09
Care setting
Hospital radiology workflow for triage and prioritization of chest and thoraco-abdominal CTA studies.
  • Exact FDA submission
  • Checked 2026-09-09
Intended users
Hospital networks and trained radiologists; notified clinicians review full images under standard of care.
  • Exact FDA submission
  • Checked 2026-09-09
Limitations
Notifications and compressed previews are informational and not for diagnosis; the device is not intended as a diagnostic device or to replace standard-of-care full-image interpretation. PE and AD are separate applications and performance endpoints.
  • Exact FDA submission
  • Checked 2026-09-09
Evidence summary
A retrospective multicenter blinded study included 396 PE cases from 230 U.S. cities/sites as stated in the packet and 298 AD cases from 200, with 190 positive PE and 137 positive AD cases; ground truth used concurrence of several U.S.-board-certified radiologists. PE sensitivity/specificity were 91.1% (95% CI 86.1%-94.7%) and 91.8% (87.1%-95.1%); AD sensitivity/specificity were 96.4% (91.7%-98.8%) and 97.5% (93.8%-99.3%). Overall agreement was 91.4% for PE and 97% for AD, MCC was 0.83 and 0.94, and mean time-to-notification was 63 seconds for PE and 36.5 seconds for AD. These are separate condition-specific sensitivity/specificity, agreement, correlation, and latency endpoints.
  • Exact FDA submission
  • Checked 2026-09-09

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
A retrospective multicenter blinded study included 396 PE cases from 230 U.S. cities/sites as stated in the packet and 298 AD cases from 200, with 190 positive PE and 137 positive AD cases; ground truth used concurrence of several U.S.-board-certified radiologists. PE sensitivity/specificity were 91.1% (95% CI 86.1%-94.7%) and 91.8% (87.1%-95.1%); AD sensitivity/specificity were 96.4% (91.7%-98.8%) and 97.5% (93.8%-99.3%). Overall agreement was 91.4% for PE and 97% for AD, MCC was 0.83 and 0.94, and mean time-to-notification was 63 seconds for PE and 36.5 seconds for AD. These are separate condition-specific sensitivity/specificity, agreement, correlation, and latency endpoints.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-09
Reported sensitivity
PE triage sensitivity: 91.1% (95% CI 86.1%-94.7%); AD triage sensitivity: 96.4% (95% CI 91.7%-98.8%); endpoints are condition-specific.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-09

The FDA packet supports separate PE and AD sensitivity endpoints and does not support one undifferentiated device-level sensitivity.

Reported specificity
PE triage specificity: 91.8% (95% CI 87.1%-95.1%); AD triage specificity: 97.5% (95% CI 93.8%-99.3%); endpoints are condition-specific.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-09

The FDA packet supports separate PE and AD specificity endpoints, retained with their labels and confidence intervals.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

CINA CHEST-PE regulatory performance study summary

  • DesignStand-Alone Performance
  • PopulationPopulation described in the exact-submission ACR model card
  • Scopeexact submission
  • Tested versionExact product version not reported; regulatory study summarized for FDA submission K210237
  • Samplen=396
  • Sites230
  • IndependenceIndependence not established

K210237

ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K210237. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-09
Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Chest CTA for suspected PE and chest or thoraco-abdominal CTA for suspected AD, received as DICOM images through the CINA Platform or a compatible medical-image communications device.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-09 · FDA K210237: CINA CHEST

  2. Routing

    Source context, not route validation: The packet describes an on-premise Worklist Application, standardized DICOM communication with CT modalities and other DICOM nodes such as routers or PACS, and output to PACS/workstations; exact local interface versions are not established.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-09 · FDA K210237: CINA CHEST

  3. AI processing

    Source context, not route validation: The exact FDA package describes CINA CHEST as running on a standard off-the-shelf server/workstation, with its image processing applications integrated, deployed and used with the CINA Platform reference device or other compatible medical image communications devices. Current hosting, data flow, and commercial configuration require vendor confirmation.

    Scope: Exact FDA submission. Packet wording: "CINA CHEST runs on a standard “off the shelf” server/workstation and is comprised of PE and AD Image Processing Applications" … "which can be integrated, deployed and used with the reference device (K200855) or other compatible medical image communications devices.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-11-14 · FDA K210237: CINA CHEST

  4. Returned objects

    Source context, not route validation: Worklist pop-up and passive icon notifications identifying suspected PE or AD, with patient name, accession number, finding type, and a compressed preview labeled not for diagnostic use; output files can be transferred to PACS or a workstation.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-09 · FDA K210237: CINA CHEST

  5. Viewer/worklist/report

    Unresolved route: Worklist pop-up and passive icon notifications identifying suspected PE or AD, with patient name, accession number, finding type, and a compressed preview labeled not for diagnostic use; output files can be transferred to PACS or a workstation.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-09 · FDA K210237: CINA CHEST

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
The exact FDA package describes CINA CHEST as running on a standard off-the-shelf server/workstation, with its image processing applications integrated, deployed and used with the CINA Platform reference device or other compatible medical image communications devices. Current hosting, data flow, and commercial configuration require vendor confirmation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "CINA CHEST runs on a standard “off the shelf” server/workstation and is comprised of PE and AD Image Processing Applications" … "which can be integrated, deployed and used with the reference device (K200855) or other compatible medical image communications devices.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

Integration
The packet describes an on-premise Worklist Application, standardized DICOM communication with CT modalities and other DICOM nodes such as routers or PACS, and output to PACS/workstations; exact local interface versions are not established.
  • Exact FDA submission
  • Checked 2026-09-09
Security
Avicenna.AI's cybersecurity page states ISO/IEC 27001 certification by SGS, IEC 81001-5-1, TLS 1.2+ in transit, encryption at rest, role-based access with least privilege, and a HIPAA business associate agreement for US customers. Vendor-wide.
  • Vendor-wide
  • Checked 2026-10-25

Vendor statement, not an attestation; exact-release scope is not established.

Input or output interoperability

DICOM is explicitly referenced in the described input, output, or workflow.

exact submission · checked 2026-09-01

The model card does not establish every supported DICOM object, transfer method, or local interface.

Supported acquisition environment

Scanner manufacturers: All

exact submission · checked 2026-09-01

Confirm currently supported software versions, protocols, and site-specific acquisition configurations.

ACR exact-submission catalog context

ACR AI Central provides an exact-submission model card for CINA CHEST; FDA labeling remains controlling for clinical use, limitations, and performance.

exact submission · checked 2026-09-09
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K210237
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
CT/CTA
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-09
Anatomy
Chest and thoraco-abdominal aorta
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-09
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2021-05-19
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-20Last searched
25Fields reviewed
10Source classes checked
1Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains 1 PubMed and 0 ClinicalTrials.gov candidate record. Discovery metadata alone does not establish exact tested-product, version, population, and endpoint applicability, so all candidates remain quarantined and none was promoted. The current discovery snapshot contains 1 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, vendor documentation, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not verified - checked 2026-09-09 - Exact FDA submission

    No public price or quote for the exact K210237 configuration was established in this review.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-09-09 - Exact FDA submission

    No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-09-09 - Exact FDA submission

    Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.

  • Monitoring: Not verified - checked 2026-09-09 - Exact FDA submission

    Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.

8 sources - 3 history items

Source ledger

  1. FDA K210237: CINA CHEST

    U.S. Food and Drug Administration - Published 2021-05-19 - Accessed 2026-09-09

    Scope: identity, clinicalUse, modality, anatomy, workflow, evidence, implementation, deployment

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. CINA CHEST-PE model card (K210237)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, output, limitations, reportedSensitivity, reportedSpecificity, evidenceSummary, integration, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. openFDA exact recall query for K210237

    U.S. Food and Drug Administration - Accessed 2026-09-09

    Scope: postmarketSafety

  8. Avicenna.AI Cybersecurity and Data Protection

    Avicenna.AI - Accessed 2026-10-25

    Scope: security

Research history

  1. K210237 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K222277

BriefCase

Aidoc Medical, Ltd.

Authorized purpose: BriefCase is a radiological computer aided triage and notification software indicated for use in the analysis of CTPA images in adults or transitional adolescents aged 18 and older. The device is intended to assist hospital networks and appropriately trained medical specialists in workflow triage by flagging and communication of suspected positive findings of Pulmonary Embolism (PE) pathologies. Briefcase uses an artificial intelligence algorithm to analyze images and highlight cases with detected findings on a Stand-Alone Performance desktop application in parallel to the ongoing standard of care image interpretation. The user is presented with notifications for cases with suspected PE findings. Notifications include compressed preview images that are meant for informational purposes only and not intended for diagnostic use beyond notification. The device does not alter the original medical image and is not intended to be used as a diagnostic device. The results of BriefCase are intended to be used in conjunction with other patient information and based on their professional judgment, to assist with triage/prioritization of medical images. Notified clinicians are responsible for viewing full images per the standard of care.

Modality
CT/CTA
Anatomy
Chest/Lung
Decision
2022-08-26
FDA-cleared K260729

Vascular Assist Occlusion Triage (VAOT) (v1.0)

GuideAI Health

Authorized purpose: Passive workflow prioritization for studies with imaging patterns consistent with possible total arterial occlusion in the specified vessels; not primary diagnosis, screening, disease detection, or patient-management decision support

Modality
CT/CTA
Anatomy
Aorta and lower-extremity arteries: common iliac, external iliac, common femoral, superficial femoral, and popliteal arteries
Decision
2026-06-18
FDA-cleared K250248

BriefCase-Triage

Aidoc Medical, Ltd.

Authorized purpose: Parallel-workflow triage and notification of suspected incidental pulmonary embolism on contrast-enhanced images that include the lungs.

Modality
CT/CTA
Anatomy
Chest and lungs
Decision
2025-02-14
FDA-cleared K240942

CINA-CSpine

Avicenna.AI

Authorized purpose: Assist hospital networks and appropriately trained physician specialists by flagging suspected acute cervical-spine fractures on cervical-spine CT for triage and prioritization; it is not designed to detect vertebral compression fractures.

Modality
CT/CTA
Anatomy
Cervical spine; acute cervical-spine fractures including non-displaced lines and displaced fragments
Decision
2024-09-12

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history